Frank LaCreta

5.6k total citations
110 papers, 4.5k citations indexed

About

Frank LaCreta is a scholar working on Molecular Biology, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Frank LaCreta has authored 110 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 29 papers in Oncology and 28 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Frank LaCreta's work include Diabetes Treatment and Management (24 papers), Atrial Fibrillation Management and Outcomes (17 papers) and Metabolism, Diabetes, and Cancer (11 papers). Frank LaCreta is often cited by papers focused on Diabetes Treatment and Management (24 papers), Atrial Fibrillation Management and Outcomes (17 papers) and Metabolism, Diabetes, and Cancer (11 papers). Frank LaCreta collaborates with scholars based in United States, Germany and Sweden. Frank LaCreta's co-authors include Charles Frost, David W. Boulton, Sreeneeranj Kasichayanula, Yu Chen Barrett, Jessie Wang, Rebecca A. Boyd, Xiaoni Liu, Steven C. Griffen, Wonkyung Byon and Alan Schuster and has published in prestigious journals such as Blood, Diabetes Care and JNCI Journal of the National Cancer Institute.

In The Last Decade

Frank LaCreta

109 papers receiving 4.4k citations

Peers

Frank LaCreta
Elvira Grandone Italy
Bianca Rocca Italy
Larisa H. Cavallari United States
Mia Wadelius Sweden
Alexandros D. Tselepis Greece
Gunnar Fager Sweden
Deepak Voora United States
Corinne Frère France
Jolanta M. Siller‐Matula Austria
Joseph A. Jakubowski United States
Elvira Grandone Italy
Frank LaCreta
Citations per year, relative to Frank LaCreta Frank LaCreta (= 1×) peers Elvira Grandone

Countries citing papers authored by Frank LaCreta

Since Specialization
Citations

This map shows the geographic impact of Frank LaCreta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank LaCreta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank LaCreta more than expected).

Fields of papers citing papers by Frank LaCreta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank LaCreta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank LaCreta. The network helps show where Frank LaCreta may publish in the future.

Co-authorship network of co-authors of Frank LaCreta

This figure shows the co-authorship network connecting the top 25 collaborators of Frank LaCreta. A scholar is included among the top collaborators of Frank LaCreta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank LaCreta. Frank LaCreta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zahir, Hamim, Ophelia Yin, Ching Hsu, et al.. (2023). Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug Development Strategy. Clinical Pharmacology in Drug Development. 12(5). 475–483. 4 indexed citations
2.
Zahir, Hamim, Jonathan Greenberg, Dale E. Shuster, et al.. (2022). Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects. Clinical Pharmacokinetics. 61(11). 1623–1639. 5 indexed citations
3.
4.
Song, Yuanlin, Zhaoqing Wang, Itay Perlstein, et al.. (2017). Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study. Journal of Thrombosis and Haemostasis. 15(11). 2125–2137. 39 indexed citations
5.
Chan, Phyllis, et al.. (2016). Using Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects to Simplify Dosing Recommendations. Clinical Pharmacokinetics. 55(12). 1559–1572. 2 indexed citations
6.
Song, Yan, Ming Chang, Robert J. Frost, et al.. (2016). Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults. Clinical Therapeutics. 38(7). 1674–1685.e1. 30 indexed citations
7.
Song, Yan, Xiaoli Wang, Itay Perlstein, et al.. (2015). Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. Clinical Therapeutics. 37(8). 1703–1712. 25 indexed citations
8.
Chang, Ming, Zhigang Yu, Andrew Shenker, et al.. (2015). Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. The Journal of Clinical Pharmacology. 56(5). 637–645. 131 indexed citations
9.
Frost, Charles, Sunil Nepal, Jessie Wang, et al.. (2013). Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factorXa inhibitor, in healthy subjects. British Journal of Clinical Pharmacology. 76(5). 776–786. 225 indexed citations
10.
Kasichayanula, Sreeneeranj, Xuejun Liu, W. Zhang, et al.. (2011). Effect of a high‐fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obesity and Metabolism. 13(8). 770–773. 39 indexed citations
11.
LaCreta, Frank, et al.. (2000). Age and Gender Effects on the Pharmacokinetics of Gatifloxacin. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 20(6P2). 67S–75S. 27 indexed citations
12.
Grasela, Dennis M., et al.. (2000). Open‐Label, Nonrandomized Study of the Effects of Gatifloxacin on the Pharmacokinetics of Midazolam in Healthy Male Volunteers. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 20(3). 330–335. 12 indexed citations
13.
Grasela, Dennis M., et al.. (2000). Safety and Pharmacokinetics of a Single Oral Dose of Gatifloxacin in Patients with Moderate to Severe Hepatic Impairment. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 20(6P2). 87S–94S. 13 indexed citations
14.
15.
Rogatko, André, Edward M. Newman, James M. Brennan, et al.. (1995). Phase I study of phosphonacetyl-l-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 35(3). 205–212. 6 indexed citations
16.
Weiner, Louis M., Elizabeth Harvey, Kristin Padavic‐Shaller, et al.. (1993). Phase II Multicenter Evaluation of Prolonged Murine Monoclonal Antibody 17-1A Therapy in Pancreatic Carcinoma. Journal of Immunotherapy. 13(2). 110–116. 35 indexed citations
17.
O’Dwyer, Peter J., et al.. (1993). SR2508 (etanidazole) pharmacokinetics and biochemical effects in tumor and normal tissues of scid mice bearing HT-29 human colon adenocarcinoma. Biochemical Pharmacology. 46(7). 1251–1256. 2 indexed citations
18.
O’Dwyer, Peter J., et al.. (1991). Chromatographic analysis of methylmercaptopurine riboside in human plasma and urine. Journal of Chromatography B Biomedical Sciences and Applications. 564(1). 303–309. 2 indexed citations
19.
LaCreta, Frank, et al.. (1989). Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. Cancer Chemotherapy and Pharmacology. 24(2). 117–22. 9 indexed citations
20.
LaCreta, Frank, et al.. (1988). Purification of glutathione S-transferases from rat liver and walker 256 mammary carcinoma cells by high-performance liquid chromatography and a glutathione affinity column. Journal of Chromatography B Biomedical Sciences and Applications. 434(1). 83–93. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elvira Grandone Breakdown of academic impact, for papers by Bianca Rocca Breakdown of academic impact, for papers by Larisa H. Cavallari Breakdown of academic impact, for papers by Mia Wadelius Breakdown of academic impact, for papers by Alexandros D. Tselepis Breakdown of academic impact, for papers by Gunnar Fager Breakdown of academic impact, for papers by Deepak Voora Breakdown of academic impact, for papers by Corinne Frère Breakdown of academic impact, for papers by Jolanta M. Siller‐Matula Breakdown of academic impact, for papers by Joseph A. Jakubowski
Rankless by CCL
2026